Search clinical trials for: factor IX

Total 36921 results

Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum; Syntonix Pharmaceuticals, Inc.

Completed

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Hemophilia B

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
University Hospital, Toulouse
Takeda; Celgene

Terminated

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma (IFM2014-03)

Multiple Myeloma

France
ISU Abxis Co., Ltd.
Catalyst Biosciences

Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Hemophilia B

Korea, Republic of
National Taiwan University Hospital

Unknown

The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients

Hemophilia

Taiwan
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Eli Lilly and Company

Completed

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3)

Psoriasis

United States, Hungary, Germany, Canada, Mexico, Bulgaria, Russian Federation, Poland, Argentina, Chile
Eli Lilly and Company

Completed

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (UNCOVER-2)

Psoriasis

United States, Germany, Spain, France, Austria, Canada, Poland, Australia, United Kingdom, Romania, Netherlands, Czechia
Pfizer

Completed

A Gene Therapy Study for Hemophilia B

Hemophilia B

United States, Australia
PTC Therapeutics
Genzyme, a Sanofi Company

Terminated

Study of Ataluren (PTC124) in Hemophilia A and B

Hemophilia A | Hemophilia B

United States, Canada, France, Italy
Spark Therapeutics
Children's Hospital of Philadelphia; Royal Prince Alfred Hospital, Sydney,... and other collaborators

Completed

LTFU for Gene Transfer Subjects With Hemophilia B

Hemophilia B

United States
Menzies School of Health Research
National Health and Medical Research Council, Australia

Completed

Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life (PREV-IX_B)

Cough | Otitis Media | Lower Respiratory Tract Infection | Febrile Illness | Upper Respiratory Tract Infection

Australia
Takeda

Terminated

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Relapsed and/or Refractory Multiple Myeloma
University of Leeds
Millennium Pharmaceuticals, Inc.; Myeloma UK

Unknown

Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (MUKEight)

Multiple Myeloma

United Kingdom
Takeda

Withdrawn

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation (IDEALL)

Multiple Myeloma

Brazil
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Czechia, Austria, Germany
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | B-cell Adult Acute Lymphoblastic Leukemia | T-cell Adult Acute Lymphoblastic Leukemia

United States
Bayer

Withdrawn

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

Hemophilia
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

Plaque Psoriasis

Germany
Eli Lilly and Company

Completed

A Study of LY2523355 in Participants With Breast Cancer

Metastatic Breast Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Poland, Greece, Australia, Sweden
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects

Healthy Volunteers

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FIX Gene Therapy

Hemophilia B
Pfizer

Terminated

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Hemophilia A | Hemophilia B

United States
Centre Hospitalier Universitaire Dijon

Unknown

Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype (Hémophilie B)

Hemophilia B

France
Xijing Hospital

Unknown

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids

China
Multinational Center for Quality of Life Research...

Unknown

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Relapsed and/or Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Spark Therapeutics
Children's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaborators

Terminated

Hemophilia B Gene Therapy With AAV8 Vector

Hemophilia B

United States, Australia
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Millennium Pharmaceuticals, Inc.

Completed

Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Hong Kong, Korea, Republic of, Singapore
Azienda Socio Sanitaria Territoriale degli Spedali...

Unknown

Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial

Prostate Cancer

Italy
Millennium Pharmaceuticals, Inc.

Completed

A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United Kingdom, Spain, Canada, United States, Czechia
PETHEMA Foundation
Millennium Pharmaceuticals, Inc.; Celgene

Completed

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Multiple Myeloma

Spain
Grifols Biologicals, LLC

Completed

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Hemophilia B

Bulgaria
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Completed

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (TITAN)

Breast Cancer

United States, Puerto Rico
University of Arkansas

Withdrawn

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Multiple Myeloma

United States
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
Eli Lilly and Company

Completed

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Healthy

United States
The Hospital for Sick Children
Canadian Hemophilia Society

Completed

An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia (HEPS)

Hemophilia A | Hemophilia B | Factor IX Deficiency | Factor VIII Deficiency

Canada
Novo Nordisk A/S

Completed

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX (DOSE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
Cangene Corporation

Withdrawn

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Hemophilia B

United Kingdom, United States
Pfizer

Completed

An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

Hemophilia B

China

Search clinical trials for: factor IX

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations